• Molecular NameFenbufen
  • SynonymNA
  • Weight254.285
  • Drugbank_IDN/A
  • ACS_NO36330-85-5
  • Show 3D model
  • LogP (experiment)3.2
  • LogP (predicted, AB/LogP v2.0)3.18
  • pka4.5
  • LogD (pH=7, predicted)0.98
  • Solubility (experiment)0.00127 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.05
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.11
  • No.of HBond Donors1
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds5
  • TPSA54.37
  • StatusN/A
  • AdministrationN/A
  • PharmacologyA non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures.
  • Absorption_valueN/A
  • Absorption (description)Readily absorbed after oral administration
  • Caco_2N/A
  • Bioavailability78.0
  • Protein binding99.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmExtensively metabolised to active metabolites. A number of metabolites have been identified including (i) 4-(biphenyl-4-yl)-4-hydroxybutyric acid, (ii) biphenyl-4-ylacetic acid, (iii) (4′-hydroxybiphenyl-4-yl)acetic acid, and (iv) 4-hydroxy-(4′-hydroxybiphenyl-4-yl)butyric acid.
  • Half lifefenbufen and metabolites (i) and (ii), ~10 h
  • ExcretionAbout 40% of a dose is excreted in the urine in 24 h. The major urinary metabolites are metabolite (iii), about 11% of the dose, and metabolite (iv), about 17% of the dose; metabolites (i) and (ii) are excreted in amounts less than about 3% of the dose. Very little unchanged drug is excreted in the urine. Less than 2% of the dose is eliminated in the faeces in 24 h.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A